Secura Bio
- Company typePrivate
- Founded2019
- HeadquartersLas Vegas, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Secura Bio firmographics
Firmographics- Name
- Secura Bio
- Legal name
- Secura Bio, Inc.
- Website
- https://securabio.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Where Secura Bio is headquartered
LocationHeadquarters
- HQ city
- Las Vegas
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Secura Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Marketing or Sales
Revenue model
- COPIKTRA (duvelisib) Product Sales: Secura Bio generates revenue through the sale of COPIKTRA, an FDA-approved oral medication for relapsed/refractory CLL/SLL. The company achieved >30% annual growth in US net sales through November 2025 and expanded distribution to Puerto Rico, EU, UK, and Israel.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels7 records
Secura Bio product offering
Product offeringCore offering
Secura Bio is an integrated biopharmaceutical company that develops and commercializes COPIKTRA (duvelisib), an oral dual inhibitor of PI3K-delta and PI3K-gamma pathways. COPIKTRA is FDA-approved for adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies, and is being clinically developed for peripheral T-cell lymphoma (PTCL) and nodal T-follicular helper cell lymphoma (nTFHL). The company also operates the Secura Care patient support program providing insurance verification, copay assistance, and reimbursement services for patients prescribed COPIKTRA.
Product overview
Secura Bio is an integrated pharmaceutical company focused on maximizing commercial outcomes for oncology medicines. Its primary product is COPIKTRA® (duvelisib), an oral dual PI3K inhibitor approved for relapsed/refractory CLL/SLL. The company is actively developing COPIKTRA for additional T-cell lymphoma indications, including peripheral T-cell lymphoma (PTCL) and nodal T-follicular helper cell lymphoma (nTFHL). Supporting the core product is the Secura Care™ patient support program, which provides insurance verification, copay assistance, and reimbursement services. The company operates through Phase 2 and Phase 3 clinical trials (PRIMO, TERZO, TEMPO) to expand the drug's therapeutic applications.
Differentiator
Problem solved
Functional benefit
Brands
- COPIKTRA: Oral inhibitor of phosphoinositide 3-kinase (PI3K), the first US approved dual inhibitor of PI3K-delta and PI3K-gamma pathways. Indicated for treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies.
Products and services
- COPIKTRA (duvelisib) Oral dual PI3K-delta and PI3K-gamma inhibitor indicated for adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies. In clinical development for peripheral T-cell lymphoma (PTCL) and nodal T-follicular helper cell lymphoma (nTFHL). Prescribed by oncologists and hematologists treating relapsed/refractory hematologic malignancies.
- Secura Care Patient support program providing insurance verification, copay support, and reimbursement resources for patients prescribed COPIKTRA.
Quantifiable outcome
- ORR 48%, CRR 33.3%, mPFS 3.4 months, mOS 12.4 months in R/R PTCL patients (n=123)
- +4 more outcomes
Companies that use Secura Bio
Customer profileSegments2 records
Ideal customer profiles2 records
Secura Bio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Secura Bio partnerships and signals
Strategic signalScale indicators4 records
Recent moves6 records
Expansion highlights5 records
Secura Bio competitors and assessment
Company assessmentDirect peers
- Verastem Oncology: Verastem was the originator of duvelisib (COPIKTRA) before Secura Bio acquired the asset. It is a commercial-stage oncology company focused on hematologic cancers, making it the most directly comparable peer in product, indication, and stage.
- MEI Pharma: MEI Pharma developed zandelisib, another oral PI3K delta inhibitor for relapsed/refractory B-cell malignancies. It shares the same PI3K class, hematology focus, and small-cap specialty pharma profile as Secura Bio.
- TG Therapeutics: TG Therapeutics developed umbralisib, a PI3K inhibitor in CLL/SLL and other hematologic malignancies, before withdrawing the program amid FDA scrutiny. It overlaps with Secura Bio in PI3K mechanism and CLL/SLL indication.
- Karyopharm Therapeutics: Karyopharm is a small commercial-stage oncology company with a single approved hematology/oncology asset (selinexor). It is closely comparable in company size, single-asset structure, and oncology focus.
Emerging players
- Rigel Pharmaceuticals: Rigel is a small-cap hematology/oncology company with multiple approved products (e.g., Tavalisse, Rezlidhia) focused on niche hematologic indications. Comparable as a small specialty hematology commercial-stage player.
- PharmaEssentia: PharmaEssentia commercializes ropeginterferon alfa-2b for polycythemia vera and is building a hematology franchise. Comparable as a smaller specialty hematology/oncology commercial-stage company pursuing rare-disease indications.
- BeiGene: BeiGene markets Brukinsa (zanubrutinib), a BTK inhibitor approved in CLL/SLL and other B-cell malignancies, and has a growing global hematology/oncology footprint. Comparable as a competing agent in Secura Bio's core indication and as an emerging global hematology player.
Broad incumbents
- Bristol-Myers Squibb: BMS markets ibrutinib (Imbruvica) and is a major player in CLL/SLL treatment. It is a broad incumbent shaping the standard of care against which COPIKTRA competes in the late-line setting.
- AbbVie: AbbVie (through the Pharmacyclics acquisition) owns Imbruvica (ibrutinib), a dominant BTK inhibitor in CLL/SLL. It defines the competitive backdrop for COPIKTRA in relapsed/refractory CLL/SLL.
- AstraZeneca: AstraZeneca markets Calquence (acalabrutinib), a leading BTK inhibitor in CLL/SLL, and is expanding its hematology portfolio. Relevant as a broad incumbent shaping CLL/SLL treatment guidelines.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Secura Bio social profiles
Digital presenceSecura Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Secura Bio leadership team
Management profileNumber of profiles
Profiles10 records
Secura Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Secura Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Secura Bio
What does Secura Bio do?
Secura Bio is an integrated biopharmaceutical company that develops and commercializes COPIKTRA (duvelisib), an oral dual inhibitor of PI3K-delta and PI3K-gamma pathways. COPIKTRA is FDA-approved for adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior therapies, and is being clinically developed for peripheral T-cell lymphoma (PTCL) and nodal T-follicular helper cell lymphoma (nTFHL). The company also operates the Secura Care patient support program providing insurance verification, copay assistance, and reimbursement services for patients prescribed COPIKTRA.
Is Secura Bio a public or private company?
Secura Bio is a private company. It is classified as private equity controlled and is currently operating.
When was Secura Bio founded?
Secura Bio was founded in 2019. It employs 11 to 50 people.
Where is Secura Bio based?
Secura Bio is headquartered in Las Vegas, United States, in the North America region.
How does Secura Bio make money?
One revenue line is on record: COPIKTRA (duvelisib) Product Sales.
Who are Secura Bio's main competitors?
Direct peers on record are Verastem Oncology, MEI Pharma, TG Therapeutics and Karyopharm Therapeutics. Emerging players are Rigel Pharmaceuticals, PharmaEssentia and BeiGene. Broad incumbents are Bristol-Myers Squibb, AbbVie and AstraZeneca.
Does Secura Bio have an API?
No public API is recorded for Secura Bio.